Walking Fish Therapeutics Closes $73 Million Series A Financing

Walking Fish Therapeutics, a leader in B cell therapeutics, today announced the completion of an oversubscribed Series A financing, raising a total of $73 million. The additional investment, co-led by Northpond Ventures and First Spark Ventures, with support from Terra Magnum Capital Partners, will be used to advance a pipeline of B cell therapeutics for oncology, rare disease, regenerative medicine, autoimmune disease, and recombinant antibody production. Walking Fish Therapeutics made its debut in September 2021 with the launch of Series A financing led by Emerson Collective, Illumina Ventures, and Quan Capital. Daniel Janse, Ph.D